[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$ftaNq6sTPToz8ADH3OB7PTwTDtOPWHQQWrOfu3iJ8kUA":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":33,"phaseBuckets":80,"rows":87},"Revolution Medicines, Inc.",[4],18,false,13,5,8315,25,0,[14,17,20,22,24,26,29,31],{"name":15,"count":16},"PDAC",7,{"name":18,"count":19},"Pancreatic Cancer",6,{"name":21,"count":9},"Colorectal Cancer (CRC)",{"name":23,"count":9},"Pancreatic Ductal Adenocarcinoma (PDAC)",{"name":25,"count":9},"PDAC - Pancreatic Ductal Adenocarcinoma",{"name":27,"count":28},"Non-small Cell Lung Cancer (NSCLC)",4,{"name":30,"count":28},"Advanced Solid Tumors",{"name":32,"count":28},"Pancreatic Adenocarcinoma",[34,39,44,49,53,57,61,66,71,75],{"nctId":35,"briefTitle":36,"date":37,"intervention":38},"NCT06040541","Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors","2026-04-30","RMC-9805",{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT06625320","Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)","2026-06","RMC-6236",{"nctId":45,"briefTitle":46,"date":47,"intervention":48},"NCT05462717","Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors","2027-03-31","RMC-6291",{"nctId":50,"briefTitle":51,"date":52,"intervention":43},"NCT06445062","Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors","2027-05-15",{"nctId":54,"briefTitle":55,"date":56,"intervention":43},"NCT05379985","Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS","2027-05-31",{"nctId":58,"briefTitle":59,"date":60,"intervention":48},"NCT06162221","Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC","2027-06",{"nctId":62,"briefTitle":63,"date":64,"intervention":65},"NCT06881784","Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)","2027-12-01","daraxonrasib",{"nctId":67,"briefTitle":68,"date":69,"intervention":70},"NCT07349537","Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors","2028-04","RMC-5127",{"nctId":72,"briefTitle":73,"date":74,"intervention":65},"NCT07491445","Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma","2028-06",{"nctId":76,"briefTitle":77,"date":78,"intervention":79},"NCT06128551","Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors","2028-12","Elironrasib",[81,82,83,84,85,86],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[88,185,253,292,322,344,366,388,410,432,450,468,494,520,546,568,586,604,622,640,658,676,694,712,730,748,799,817,835,853],{"intervention":65,"totalTrials":16,"cells":89},{"EARLY_PHASE1":90,"PHASE1":92,"PHASE2":107,"PHASE3":134,"PHASE4":173,"NA":175},{"trials":91,"activeCount":12},[],{"trials":93,"activeCount":106,"soonestReadout":69},[94],{"nctId":67,"briefTitle":68,"status":95,"phases":96,"primaryCompletion":69,"completion":97,"start":98,"enrollment":99,"conditions":100,"interventions":104},"RECRUITING",[82],"2028-10","2026-01-08",574,[27,21,32,23,15,101,102,18,103,30],"CRC","NSCLC","Lung Cancer (NSCLC)",[70,65,105],"cetuximab",1,{"trials":108,"activeCount":133,"soonestReadout":78},[109,123],{"nctId":110,"briefTitle":111,"status":95,"phases":112,"primaryCompletion":113,"completion":113,"start":114,"enrollment":115,"conditions":116,"interventions":118},"NCT07397338","Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors",[82,83],"2029-05","2026-01-30",370,[30,117,27,102,21,101],"Metastatic Solid Tumors",[119,79,120,121,122,105,122,119],"Daraxonrasib","Zoldonrasib","Ivonescimab","Carboplatin\u002FCisplatin + Pemetrexed",{"nctId":76,"briefTitle":77,"status":95,"phases":124,"primaryCompletion":78,"completion":125,"start":126,"enrollment":127,"conditions":128,"interventions":132},[82,83],"2029-06","2023-11-14",534,[129,130,131],"Non-Small Cell Lung Cancer (NSCLC)","Colorectal Cancer","Pancreatic Ductal Adenocarcinoma",[79,119],2,{"trials":135,"activeCount":172,"soonestReadout":64},[136,148,160],{"nctId":137,"briefTitle":138,"status":95,"phases":139,"primaryCompletion":140,"completion":141,"start":142,"enrollment":143,"conditions":144,"interventions":147},"NCT07252232","Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)",[84],"2029-05-10","2030-07-10","2025-12-15",500,[18,15,25,145,146],"Resectable Pancreatic Ductal Adenocarcinoma (PDAC)","Resected Pancreatic Adenocarcinoma",[65],{"nctId":72,"briefTitle":73,"status":95,"phases":149,"primaryCompletion":74,"completion":150,"start":151,"enrollment":152,"conditions":153,"interventions":157},[84],"2029-03","2026-03-09",900,[18,154,15,25,23,155,32,156],"Pancreatic Cancer Metastatic","Pancreatic Adenocarcinoma Metastatic","Pancreatic Adenosquamous Carcinoma",[65,158,159],"gemcitabine","nab-paclitaxel",{"nctId":62,"briefTitle":63,"status":95,"phases":161,"primaryCompletion":64,"completion":162,"start":163,"enrollment":164,"conditions":165,"interventions":170},[84],"2030-12-01","2025-05-06",590,[166,167,102,168,169],"NSCLC (Non-small Cell Lung Cancer)","Non-Small Cell Lung Cancer","NSCLC (Non-small Cell Lung Carcinoma)","NSCLC (Advanced Non-small Cell Lung Cancer)",[65,171],"docetaxel",3,{"trials":174,"activeCount":12},[],{"trials":176,"activeCount":12},[177],{"nctId":178,"briefTitle":179,"status":180,"phases":181,"conditions":182,"interventions":184},"NCT07573215","Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Adenocarcinoma","AVAILABLE",[],[15,25,183,18,154,155,32,156],"Metastatic Pancreas Adenocarcinoma",[65],{"intervention":43,"totalTrials":9,"cells":186},{"EARLY_PHASE1":187,"PHASE1":189,"PHASE2":198,"PHASE3":234,"PHASE4":249,"NA":251},{"trials":188,"activeCount":12},[],{"trials":190,"activeCount":106,"soonestReadout":37},[191],{"nctId":35,"briefTitle":36,"status":95,"phases":192,"primaryCompletion":37,"completion":193,"start":194,"enrollment":195,"conditions":196,"interventions":197},[82],"2027-04-30","2023-09-07",604,[27,21,23,30],[38,43],{"trials":199,"activeCount":172,"soonestReadout":52},[200,215,227],{"nctId":58,"briefTitle":59,"status":95,"phases":201,"primaryCompletion":60,"completion":78,"start":202,"enrollment":203,"conditions":204,"interventions":210},[82,83],"2024-01-18",616,[205,206,207,208,209],"Non-Small Cell Lung Cancer, NSCLC","KRAS, NRAS, HRAS-mutated NSCLC","KRAS G12C-mutated Solid Tumors, Lung Cancer","Lung Cancer Stage IV, Advanced Solid Tumor, Cancer","RAS G12D-mutated NSCLC",[48,43,211,212,213,214,38],"Pembrolizumab","Cisplatin","Carboplatin","Pemetrexed",{"nctId":50,"briefTitle":51,"status":95,"phases":216,"primaryCompletion":52,"completion":217,"start":218,"enrollment":219,"conditions":220,"interventions":223},[82,83],"2027-07-15","2024-05-24",1130,[130,101,131,15,221,222],"Gastrointestinal Cancer","Metastatic Pancreatic Ductal Adenocarcinoma",[43,224,225,226,105,158,159,38],"mFOLFOX6 regimen","bevacizumab","mFOLFIRINOX regimen",{"nctId":54,"briefTitle":55,"status":95,"phases":228,"primaryCompletion":56,"completion":229,"start":230,"enrollment":231,"conditions":232,"interventions":233},[82,83],"2027-07-26","2022-05-31",754,[27,21,23,30],[43],{"trials":235,"activeCount":106,"soonestReadout":42},[236],{"nctId":40,"briefTitle":41,"status":237,"phases":238,"primaryCompletion":42,"completion":239,"start":240,"enrollment":143,"conditions":241,"interventions":242},"ACTIVE_NOT_RECRUITING",[84],"2027-12","2024-10-16",[18,15,25],[43,243,159,244,245,246,247,248],"Gemcitabine","Irinotecan","Liposomal irinotecan","5-fluorouracil","leucovorin","Oxaliplatin",{"trials":250,"activeCount":12},[],{"trials":252,"activeCount":12},[],{"intervention":243,"totalTrials":28,"cells":254},{"EARLY_PHASE1":255,"PHASE1":257,"PHASE2":259,"PHASE3":265,"PHASE4":288,"NA":290},{"trials":256,"activeCount":12},[],{"trials":258,"activeCount":12},[],{"trials":260,"activeCount":106,"soonestReadout":52},[261],{"nctId":50,"briefTitle":51,"status":95,"phases":262,"primaryCompletion":52,"completion":217,"start":218,"enrollment":219,"conditions":263,"interventions":264},[82,83],[130,101,131,15,221,222],[43,224,225,226,105,158,159,38],{"trials":266,"activeCount":172,"soonestReadout":42},[267,280,284],{"nctId":268,"briefTitle":269,"status":95,"phases":270,"primaryCompletion":271,"completion":272,"start":273,"enrollment":274,"conditions":275,"interventions":276},"NCT07621718","Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )",[84],"2028-12-30","2030-04-22","2026-05-22",670,[18,154,15,25,23,155,32,156],[120,248,277,278,244,243,279],"Leucovorin","5-Fluorouracil","Nab-paclitaxel",{"nctId":72,"briefTitle":73,"status":95,"phases":281,"primaryCompletion":74,"completion":150,"start":151,"enrollment":152,"conditions":282,"interventions":283},[84],[18,154,15,25,23,155,32,156],[65,158,159],{"nctId":40,"briefTitle":41,"status":237,"phases":285,"primaryCompletion":42,"completion":239,"start":240,"enrollment":143,"conditions":286,"interventions":287},[84],[18,15,25],[43,243,159,244,245,246,247,248],{"trials":289,"activeCount":12},[],{"trials":291,"activeCount":12},[],{"intervention":159,"totalTrials":28,"cells":293},{"EARLY_PHASE1":294,"PHASE1":296,"PHASE2":298,"PHASE3":304,"PHASE4":318,"NA":320},{"trials":295,"activeCount":12},[],{"trials":297,"activeCount":12},[],{"trials":299,"activeCount":106,"soonestReadout":52},[300],{"nctId":50,"briefTitle":51,"status":95,"phases":301,"primaryCompletion":52,"completion":217,"start":218,"enrollment":219,"conditions":302,"interventions":303},[82,83],[130,101,131,15,221,222],[43,224,225,226,105,158,159,38],{"trials":305,"activeCount":172,"soonestReadout":42},[306,310,314],{"nctId":268,"briefTitle":269,"status":95,"phases":307,"primaryCompletion":271,"completion":272,"start":273,"enrollment":274,"conditions":308,"interventions":309},[84],[18,154,15,25,23,155,32,156],[120,248,277,278,244,243,279],{"nctId":72,"briefTitle":73,"status":95,"phases":311,"primaryCompletion":74,"completion":150,"start":151,"enrollment":152,"conditions":312,"interventions":313},[84],[18,154,15,25,23,155,32,156],[65,158,159],{"nctId":40,"briefTitle":41,"status":237,"phases":315,"primaryCompletion":42,"completion":239,"start":240,"enrollment":143,"conditions":316,"interventions":317},[84],[18,15,25],[43,243,159,244,245,246,247,248],{"trials":319,"activeCount":12},[],{"trials":321,"activeCount":12},[],{"intervention":120,"totalTrials":133,"cells":323},{"EARLY_PHASE1":324,"PHASE1":326,"PHASE2":328,"PHASE3":334,"PHASE4":340,"NA":342},{"trials":325,"activeCount":12},[],{"trials":327,"activeCount":12},[],{"trials":329,"activeCount":106,"soonestReadout":113},[330],{"nctId":110,"briefTitle":111,"status":95,"phases":331,"primaryCompletion":113,"completion":113,"start":114,"enrollment":115,"conditions":332,"interventions":333},[82,83],[30,117,27,102,21,101],[119,79,120,121,122,105,122,119],{"trials":335,"activeCount":106,"soonestReadout":271},[336],{"nctId":268,"briefTitle":269,"status":95,"phases":337,"primaryCompletion":271,"completion":272,"start":273,"enrollment":274,"conditions":338,"interventions":339},[84],[18,154,15,25,23,155,32,156],[120,248,277,278,244,243,279],{"trials":341,"activeCount":12},[],{"trials":343,"activeCount":12},[],{"intervention":248,"totalTrials":133,"cells":345},{"EARLY_PHASE1":346,"PHASE1":348,"PHASE2":350,"PHASE3":352,"PHASE4":362,"NA":364},{"trials":347,"activeCount":12},[],{"trials":349,"activeCount":12},[],{"trials":351,"activeCount":12},[],{"trials":353,"activeCount":133,"soonestReadout":42},[354,358],{"nctId":268,"briefTitle":269,"status":95,"phases":355,"primaryCompletion":271,"completion":272,"start":273,"enrollment":274,"conditions":356,"interventions":357},[84],[18,154,15,25,23,155,32,156],[120,248,277,278,244,243,279],{"nctId":40,"briefTitle":41,"status":237,"phases":359,"primaryCompletion":42,"completion":239,"start":240,"enrollment":143,"conditions":360,"interventions":361},[84],[18,15,25],[43,243,159,244,245,246,247,248],{"trials":363,"activeCount":12},[],{"trials":365,"activeCount":12},[],{"intervention":277,"totalTrials":133,"cells":367},{"EARLY_PHASE1":368,"PHASE1":370,"PHASE2":372,"PHASE3":374,"PHASE4":384,"NA":386},{"trials":369,"activeCount":12},[],{"trials":371,"activeCount":12},[],{"trials":373,"activeCount":12},[],{"trials":375,"activeCount":133,"soonestReadout":42},[376,380],{"nctId":268,"briefTitle":269,"status":95,"phases":377,"primaryCompletion":271,"completion":272,"start":273,"enrollment":274,"conditions":378,"interventions":379},[84],[18,154,15,25,23,155,32,156],[120,248,277,278,244,243,279],{"nctId":40,"briefTitle":41,"status":237,"phases":381,"primaryCompletion":42,"completion":239,"start":240,"enrollment":143,"conditions":382,"interventions":383},[84],[18,15,25],[43,243,159,244,245,246,247,248],{"trials":385,"activeCount":12},[],{"trials":387,"activeCount":12},[],{"intervention":278,"totalTrials":133,"cells":389},{"EARLY_PHASE1":390,"PHASE1":392,"PHASE2":394,"PHASE3":396,"PHASE4":406,"NA":408},{"trials":391,"activeCount":12},[],{"trials":393,"activeCount":12},[],{"trials":395,"activeCount":12},[],{"trials":397,"activeCount":133,"soonestReadout":42},[398,402],{"nctId":268,"briefTitle":269,"status":95,"phases":399,"primaryCompletion":271,"completion":272,"start":273,"enrollment":274,"conditions":400,"interventions":401},[84],[18,154,15,25,23,155,32,156],[120,248,277,278,244,243,279],{"nctId":40,"briefTitle":41,"status":237,"phases":403,"primaryCompletion":42,"completion":239,"start":240,"enrollment":143,"conditions":404,"interventions":405},[84],[18,15,25],[43,243,159,244,245,246,247,248],{"trials":407,"activeCount":12},[],{"trials":409,"activeCount":12},[],{"intervention":244,"totalTrials":133,"cells":411},{"EARLY_PHASE1":412,"PHASE1":414,"PHASE2":416,"PHASE3":418,"PHASE4":428,"NA":430},{"trials":413,"activeCount":12},[],{"trials":415,"activeCount":12},[],{"trials":417,"activeCount":12},[],{"trials":419,"activeCount":133,"soonestReadout":42},[420,424],{"nctId":268,"briefTitle":269,"status":95,"phases":421,"primaryCompletion":271,"completion":272,"start":273,"enrollment":274,"conditions":422,"interventions":423},[84],[18,154,15,25,23,155,32,156],[120,248,277,278,244,243,279],{"nctId":40,"briefTitle":41,"status":237,"phases":425,"primaryCompletion":42,"completion":239,"start":240,"enrollment":143,"conditions":426,"interventions":427},[84],[18,15,25],[43,243,159,244,245,246,247,248],{"trials":429,"activeCount":12},[],{"trials":431,"activeCount":12},[],{"intervention":245,"totalTrials":106,"cells":433},{"EARLY_PHASE1":434,"PHASE1":436,"PHASE2":438,"PHASE3":440,"PHASE4":446,"NA":448},{"trials":435,"activeCount":12},[],{"trials":437,"activeCount":12},[],{"trials":439,"activeCount":12},[],{"trials":441,"activeCount":106,"soonestReadout":42},[442],{"nctId":40,"briefTitle":41,"status":237,"phases":443,"primaryCompletion":42,"completion":239,"start":240,"enrollment":143,"conditions":444,"interventions":445},[84],[18,15,25],[43,243,159,244,245,246,247,248],{"trials":447,"activeCount":12},[],{"trials":449,"activeCount":12},[],{"intervention":171,"totalTrials":106,"cells":451},{"EARLY_PHASE1":452,"PHASE1":454,"PHASE2":456,"PHASE3":458,"PHASE4":464,"NA":466},{"trials":453,"activeCount":12},[],{"trials":455,"activeCount":12},[],{"trials":457,"activeCount":12},[],{"trials":459,"activeCount":106,"soonestReadout":64},[460],{"nctId":62,"briefTitle":63,"status":95,"phases":461,"primaryCompletion":64,"completion":162,"start":163,"enrollment":164,"conditions":462,"interventions":463},[84],[166,167,102,168,169],[65,171],{"trials":465,"activeCount":12},[],{"trials":467,"activeCount":12},[],{"intervention":38,"totalTrials":172,"cells":469},{"EARLY_PHASE1":470,"PHASE1":472,"PHASE2":478,"PHASE3":488,"PHASE4":490,"NA":492},{"trials":471,"activeCount":12},[],{"trials":473,"activeCount":106,"soonestReadout":37},[474],{"nctId":35,"briefTitle":36,"status":95,"phases":475,"primaryCompletion":37,"completion":193,"start":194,"enrollment":195,"conditions":476,"interventions":477},[82],[27,21,23,30],[38,43],{"trials":479,"activeCount":133,"soonestReadout":52},[480,484],{"nctId":58,"briefTitle":59,"status":95,"phases":481,"primaryCompletion":60,"completion":78,"start":202,"enrollment":203,"conditions":482,"interventions":483},[82,83],[205,206,207,208,209],[48,43,211,212,213,214,38],{"nctId":50,"briefTitle":51,"status":95,"phases":485,"primaryCompletion":52,"completion":217,"start":218,"enrollment":219,"conditions":486,"interventions":487},[82,83],[130,101,131,15,221,222],[43,224,225,226,105,158,159,38],{"trials":489,"activeCount":12},[],{"trials":491,"activeCount":12},[],{"trials":493,"activeCount":12},[],{"intervention":105,"totalTrials":172,"cells":495},{"EARLY_PHASE1":496,"PHASE1":498,"PHASE2":504,"PHASE3":514,"PHASE4":516,"NA":518},{"trials":497,"activeCount":12},[],{"trials":499,"activeCount":106,"soonestReadout":69},[500],{"nctId":67,"briefTitle":68,"status":95,"phases":501,"primaryCompletion":69,"completion":97,"start":98,"enrollment":99,"conditions":502,"interventions":503},[82],[27,21,32,23,15,101,102,18,103,30],[70,65,105],{"trials":505,"activeCount":133,"soonestReadout":52},[506,510],{"nctId":50,"briefTitle":51,"status":95,"phases":507,"primaryCompletion":52,"completion":217,"start":218,"enrollment":219,"conditions":508,"interventions":509},[82,83],[130,101,131,15,221,222],[43,224,225,226,105,158,159,38],{"nctId":110,"briefTitle":111,"status":95,"phases":511,"primaryCompletion":113,"completion":113,"start":114,"enrollment":115,"conditions":512,"interventions":513},[82,83],[30,117,27,102,21,101],[119,79,120,121,122,105,122,119],{"trials":515,"activeCount":12},[],{"trials":517,"activeCount":12},[],{"trials":519,"activeCount":12},[],{"intervention":48,"totalTrials":133,"cells":521},{"EARLY_PHASE1":522,"PHASE1":524,"PHASE2":534,"PHASE3":540,"PHASE4":542,"NA":544},{"trials":523,"activeCount":12},[],{"trials":525,"activeCount":106,"soonestReadout":47},[526],{"nctId":45,"briefTitle":46,"status":237,"phases":527,"primaryCompletion":47,"completion":528,"start":529,"enrollment":530,"conditions":531,"interventions":533},[82],"2027-09-30","2022-09-19",222,[129,21,131,532],"Advanced Solid Tumor",[48],{"trials":535,"activeCount":106,"soonestReadout":60},[536],{"nctId":58,"briefTitle":59,"status":95,"phases":537,"primaryCompletion":60,"completion":78,"start":202,"enrollment":203,"conditions":538,"interventions":539},[82,83],[205,206,207,208,209],[48,43,211,212,213,214,38],{"trials":541,"activeCount":12},[],{"trials":543,"activeCount":12},[],{"trials":545,"activeCount":12},[],{"intervention":79,"totalTrials":133,"cells":547},{"EARLY_PHASE1":548,"PHASE1":550,"PHASE2":552,"PHASE3":562,"PHASE4":564,"NA":566},{"trials":549,"activeCount":12},[],{"trials":551,"activeCount":12},[],{"trials":553,"activeCount":133,"soonestReadout":78},[554,558],{"nctId":110,"briefTitle":111,"status":95,"phases":555,"primaryCompletion":113,"completion":113,"start":114,"enrollment":115,"conditions":556,"interventions":557},[82,83],[30,117,27,102,21,101],[119,79,120,121,122,105,122,119],{"nctId":76,"briefTitle":77,"status":95,"phases":559,"primaryCompletion":78,"completion":125,"start":126,"enrollment":127,"conditions":560,"interventions":561},[82,83],[129,130,131],[79,119],{"trials":563,"activeCount":12},[],{"trials":565,"activeCount":12},[],{"trials":567,"activeCount":12},[],{"intervention":211,"totalTrials":106,"cells":569},{"EARLY_PHASE1":570,"PHASE1":572,"PHASE2":574,"PHASE3":580,"PHASE4":582,"NA":584},{"trials":571,"activeCount":12},[],{"trials":573,"activeCount":12},[],{"trials":575,"activeCount":106,"soonestReadout":60},[576],{"nctId":58,"briefTitle":59,"status":95,"phases":577,"primaryCompletion":60,"completion":78,"start":202,"enrollment":203,"conditions":578,"interventions":579},[82,83],[205,206,207,208,209],[48,43,211,212,213,214,38],{"trials":581,"activeCount":12},[],{"trials":583,"activeCount":12},[],{"trials":585,"activeCount":12},[],{"intervention":212,"totalTrials":106,"cells":587},{"EARLY_PHASE1":588,"PHASE1":590,"PHASE2":592,"PHASE3":598,"PHASE4":600,"NA":602},{"trials":589,"activeCount":12},[],{"trials":591,"activeCount":12},[],{"trials":593,"activeCount":106,"soonestReadout":60},[594],{"nctId":58,"briefTitle":59,"status":95,"phases":595,"primaryCompletion":60,"completion":78,"start":202,"enrollment":203,"conditions":596,"interventions":597},[82,83],[205,206,207,208,209],[48,43,211,212,213,214,38],{"trials":599,"activeCount":12},[],{"trials":601,"activeCount":12},[],{"trials":603,"activeCount":12},[],{"intervention":213,"totalTrials":106,"cells":605},{"EARLY_PHASE1":606,"PHASE1":608,"PHASE2":610,"PHASE3":616,"PHASE4":618,"NA":620},{"trials":607,"activeCount":12},[],{"trials":609,"activeCount":12},[],{"trials":611,"activeCount":106,"soonestReadout":60},[612],{"nctId":58,"briefTitle":59,"status":95,"phases":613,"primaryCompletion":60,"completion":78,"start":202,"enrollment":203,"conditions":614,"interventions":615},[82,83],[205,206,207,208,209],[48,43,211,212,213,214,38],{"trials":617,"activeCount":12},[],{"trials":619,"activeCount":12},[],{"trials":621,"activeCount":12},[],{"intervention":214,"totalTrials":106,"cells":623},{"EARLY_PHASE1":624,"PHASE1":626,"PHASE2":628,"PHASE3":634,"PHASE4":636,"NA":638},{"trials":625,"activeCount":12},[],{"trials":627,"activeCount":12},[],{"trials":629,"activeCount":106,"soonestReadout":60},[630],{"nctId":58,"briefTitle":59,"status":95,"phases":631,"primaryCompletion":60,"completion":78,"start":202,"enrollment":203,"conditions":632,"interventions":633},[82,83],[205,206,207,208,209],[48,43,211,212,213,214,38],{"trials":635,"activeCount":12},[],{"trials":637,"activeCount":12},[],{"trials":639,"activeCount":12},[],{"intervention":224,"totalTrials":106,"cells":641},{"EARLY_PHASE1":642,"PHASE1":644,"PHASE2":646,"PHASE3":652,"PHASE4":654,"NA":656},{"trials":643,"activeCount":12},[],{"trials":645,"activeCount":12},[],{"trials":647,"activeCount":106,"soonestReadout":52},[648],{"nctId":50,"briefTitle":51,"status":95,"phases":649,"primaryCompletion":52,"completion":217,"start":218,"enrollment":219,"conditions":650,"interventions":651},[82,83],[130,101,131,15,221,222],[43,224,225,226,105,158,159,38],{"trials":653,"activeCount":12},[],{"trials":655,"activeCount":12},[],{"trials":657,"activeCount":12},[],{"intervention":225,"totalTrials":106,"cells":659},{"EARLY_PHASE1":660,"PHASE1":662,"PHASE2":664,"PHASE3":670,"PHASE4":672,"NA":674},{"trials":661,"activeCount":12},[],{"trials":663,"activeCount":12},[],{"trials":665,"activeCount":106,"soonestReadout":52},[666],{"nctId":50,"briefTitle":51,"status":95,"phases":667,"primaryCompletion":52,"completion":217,"start":218,"enrollment":219,"conditions":668,"interventions":669},[82,83],[130,101,131,15,221,222],[43,224,225,226,105,158,159,38],{"trials":671,"activeCount":12},[],{"trials":673,"activeCount":12},[],{"trials":675,"activeCount":12},[],{"intervention":226,"totalTrials":106,"cells":677},{"EARLY_PHASE1":678,"PHASE1":680,"PHASE2":682,"PHASE3":688,"PHASE4":690,"NA":692},{"trials":679,"activeCount":12},[],{"trials":681,"activeCount":12},[],{"trials":683,"activeCount":106,"soonestReadout":52},[684],{"nctId":50,"briefTitle":51,"status":95,"phases":685,"primaryCompletion":52,"completion":217,"start":218,"enrollment":219,"conditions":686,"interventions":687},[82,83],[130,101,131,15,221,222],[43,224,225,226,105,158,159,38],{"trials":689,"activeCount":12},[],{"trials":691,"activeCount":12},[],{"trials":693,"activeCount":12},[],{"intervention":121,"totalTrials":106,"cells":695},{"EARLY_PHASE1":696,"PHASE1":698,"PHASE2":700,"PHASE3":706,"PHASE4":708,"NA":710},{"trials":697,"activeCount":12},[],{"trials":699,"activeCount":12},[],{"trials":701,"activeCount":106,"soonestReadout":113},[702],{"nctId":110,"briefTitle":111,"status":95,"phases":703,"primaryCompletion":113,"completion":113,"start":114,"enrollment":115,"conditions":704,"interventions":705},[82,83],[30,117,27,102,21,101],[119,79,120,121,122,105,122,119],{"trials":707,"activeCount":12},[],{"trials":709,"activeCount":12},[],{"trials":711,"activeCount":12},[],{"intervention":122,"totalTrials":106,"cells":713},{"EARLY_PHASE1":714,"PHASE1":716,"PHASE2":718,"PHASE3":724,"PHASE4":726,"NA":728},{"trials":715,"activeCount":12},[],{"trials":717,"activeCount":12},[],{"trials":719,"activeCount":106,"soonestReadout":113},[720],{"nctId":110,"briefTitle":111,"status":95,"phases":721,"primaryCompletion":113,"completion":113,"start":114,"enrollment":115,"conditions":722,"interventions":723},[82,83],[30,117,27,102,21,101],[119,79,120,121,122,105,122,119],{"trials":725,"activeCount":12},[],{"trials":727,"activeCount":12},[],{"trials":729,"activeCount":12},[],{"intervention":70,"totalTrials":106,"cells":731},{"EARLY_PHASE1":732,"PHASE1":734,"PHASE2":740,"PHASE3":742,"PHASE4":744,"NA":746},{"trials":733,"activeCount":12},[],{"trials":735,"activeCount":106,"soonestReadout":69},[736],{"nctId":67,"briefTitle":68,"status":95,"phases":737,"primaryCompletion":69,"completion":97,"start":98,"enrollment":99,"conditions":738,"interventions":739},[82],[27,21,32,23,15,101,102,18,103,30],[70,65,105],{"trials":741,"activeCount":12},[],{"trials":743,"activeCount":12},[],{"trials":745,"activeCount":12},[],{"trials":747,"activeCount":12},[],{"intervention":749,"totalTrials":172,"cells":750},"RMC-4630",{"EARLY_PHASE1":751,"PHASE1":753,"PHASE2":767,"PHASE3":793,"PHASE4":795,"NA":797},{"trials":752,"activeCount":12},[],{"trials":754,"activeCount":12},[755],{"nctId":756,"briefTitle":757,"status":758,"phases":759,"primaryCompletion":760,"completion":761,"start":762,"enrollment":763,"conditions":764,"interventions":766},"NCT03634982","Dose Escalation of RMC-4630 Monotherapy in Relapsed\u002FRefractory Solid Tumors","UNKNOWN",[82],"2023-03-31","2023-05-31","2018-09-28",133,[765],"Solid Tumors",[749],{"trials":768,"activeCount":12},[769,782],{"nctId":770,"briefTitle":771,"status":772,"phases":773,"primaryCompletion":774,"completion":774,"start":775,"enrollment":776,"conditions":777,"interventions":779},"NCT03989115","Dose-Esc\u002FExp RMC4630 & Cobi in Relapsed\u002FRefractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv\u002FMeta NSCLC","COMPLETED",[82,83],"2022-02-08","2019-07-02",113,[778],"Solid Tumor",[749,780,781],"Cobimetinib","Drug: Osimertinib",{"nctId":783,"briefTitle":784,"status":772,"phases":785,"primaryCompletion":786,"completion":787,"start":788,"enrollment":789,"conditions":790,"interventions":791},"NCT05054725","Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies",[83],"2024-07-03","2024-08-29","2021-12-30",47,[167],[749,792],"Sotorasib",{"trials":794,"activeCount":12},[],{"trials":796,"activeCount":12},[],{"trials":798,"activeCount":12},[],{"intervention":780,"totalTrials":106,"cells":800},{"EARLY_PHASE1":801,"PHASE1":803,"PHASE2":805,"PHASE3":811,"PHASE4":813,"NA":815},{"trials":802,"activeCount":12},[],{"trials":804,"activeCount":12},[],{"trials":806,"activeCount":12},[807],{"nctId":770,"briefTitle":771,"status":772,"phases":808,"primaryCompletion":774,"completion":774,"start":775,"enrollment":776,"conditions":809,"interventions":810},[82,83],[778],[749,780,781],{"trials":812,"activeCount":12},[],{"trials":814,"activeCount":12},[],{"trials":816,"activeCount":12},[],{"intervention":781,"totalTrials":106,"cells":818},{"EARLY_PHASE1":819,"PHASE1":821,"PHASE2":823,"PHASE3":829,"PHASE4":831,"NA":833},{"trials":820,"activeCount":12},[],{"trials":822,"activeCount":12},[],{"trials":824,"activeCount":12},[825],{"nctId":770,"briefTitle":771,"status":772,"phases":826,"primaryCompletion":774,"completion":774,"start":775,"enrollment":776,"conditions":827,"interventions":828},[82,83],[778],[749,780,781],{"trials":830,"activeCount":12},[],{"trials":832,"activeCount":12},[],{"trials":834,"activeCount":12},[],{"intervention":792,"totalTrials":106,"cells":836},{"EARLY_PHASE1":837,"PHASE1":839,"PHASE2":841,"PHASE3":847,"PHASE4":849,"NA":851},{"trials":838,"activeCount":12},[],{"trials":840,"activeCount":12},[],{"trials":842,"activeCount":12},[843],{"nctId":783,"briefTitle":784,"status":772,"phases":844,"primaryCompletion":786,"completion":787,"start":788,"enrollment":789,"conditions":845,"interventions":846},[83],[167],[749,792],{"trials":848,"activeCount":12},[],{"trials":850,"activeCount":12},[],{"trials":852,"activeCount":12},[],{"intervention":854,"totalTrials":106,"cells":855},"RMC-5552",{"EARLY_PHASE1":856,"PHASE1":858,"PHASE2":870,"PHASE3":872,"PHASE4":874,"NA":876},{"trials":857,"activeCount":12},[],{"trials":859,"activeCount":12},[860],{"nctId":861,"briefTitle":862,"status":772,"phases":863,"primaryCompletion":864,"completion":865,"start":866,"enrollment":867,"conditions":868,"interventions":869},"NCT04774952","Dose Escalation of RMC-5552 Monotherapy in Relapsed\u002FRefractory Solid Tumors",[82],"2024-05-06","2024-06-28","2021-04-07",58,[765],[854],{"trials":871,"activeCount":12},[],{"trials":873,"activeCount":12},[],{"trials":875,"activeCount":12},[],{"trials":877,"activeCount":12},[]]